The interrelationship between platinum resistance and clinical response is not well established. The purpose of this study is to evaluate the expression of 14 genes involved in platinum resistance in a colon cancer cell line (HT29) and its oxaliplatin (OXA)-resistant sublines. Resistant cells exhibited lower expression of many of these genes suggesting
C, Plasencia +5 more
openaire +3 more sources
T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities
T cell exhaustion limits immunotherapy efficacy. This article delineates its progression from stem‐like to terminally exhausted states, governed by persistent antigen, transcription factors, epigenetics, and metabolism. It maps the exhaustion landscape in the TME and proposes integrated reversal strategies, providing a translational roadmap to overcome
Yang Yu +7 more
wiley +1 more source
Inhibition of PI3K increases oxaliplatin sensitivity in cholangiocarcinoma cells
Background Resistance of cholangiocarcinoma to chemotherapy is a major problem in cancer treatment. The mechanism of resistance is believed to involve phosphoinositide-3- kinase (PI3K)/Akt activation. Although the platinum-containing compound oxaliplatin
Udomchaiprasertkul Wandee +4 more
doaj +1 more source
FAM129B, an antioxidative protein, reduces chemosensitivity by competing with Nrf2 for Keap1 binding. [PDF]
BackgroundThe transcription factor Nrf2 is a master regulator of antioxidant response. While Nrf2 activation may counter increasing oxidative stress in aging, its activation in cancer can promote cancer progression and metastasis, and confer resistance ...
Cheng, Jing-Yan +9 more
core +1 more source
A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship [PDF]
We undertook a systematic review of the pre-clinical and clinical literature for studies investigating the relationship between platinum and taxane resistance.
Davey, Ross +2 more
core +1 more source
Anti-tumor effects of CIK combined with oxaliplatin in human oxaliplatin-resistant gastric cancer cells in vivo and in vitro [PDF]
AbstractBackgroundDrug resistance remains a great challenge in the treatment of gastric cancer. The goal of this study was to explore the anti-tumor effects and mechanism of cytokine-induced killer (CIK) cell combined with oxaliplatin (L-OHP) in human oxaliplatin-resistant gastric cancer cells.MethodsAfter producing oxaliplatin-resistant gastric cancer
Zhao Qun +5 more
openaire +3 more sources
HNRNPD promotes radioresistance in nasopharyngeal carcinoma by enhancing stress granule assembly and sequestering GRAMD4 mRNA. This suppresses GRAMD4 translation and inhibits mitochondrial apoptosis. Targeting the integrated stress response with ISRIB restores GRAMD4 expression and sensitizes tumors to radiotherapy, revealing a translational control ...
Yingzi Li +13 more
wiley +1 more source
sEVs‐circ6718 serves as a promising serum biomarker for gastric cancer early diagnosis and prognosis, promoting malignant transformation in gastric cancer cells and GC‑MSC differentiation into CAFs. sEVs‑circ6718 holds potential as a biomarker for the early diagnosis and prognostic assessment of gastric cancer.
Fan Zhang +7 more
wiley +1 more source
Treatment of CD30-Expressing Germ Cell Tumors and Sex Cord Stromal Tumors with Brentuximab Vedotin: Identification and Report of Seven Cases [PDF]
BACKGROUND: Cytotoxic therapy for relapsed and refractory germ cell tumors or metastatic sex cord stromal tumors is rarely effective and is often accompanied by high adverse event rates.
Albany, Costantine +5 more
core +1 more source
Leveraging Artificial Intelligence and Large Language Models for Cancer Immunotherapy
Cancer immunotherapy faces challenges in predicting treatment responses and understanding resistance mechanisms. Artificial intelligence (AI) and machine learning (ML) offer powerful solutions for cancer immunotherapy in patient stratification, biomarker discovery, treatment strategy optimization, and foundation model development.
Xinchao Wu +4 more
wiley +1 more source

